Navigation Links
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Date:10/19/2009

EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study (5,6).

The Phase III clinical trial, Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients (ENESTnd), is the largest global randomized comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients. Designed to detect a difference in major molecular response (MMR) between Tasigna and Gleevec after 12 months of treatment, it is also the first registration study in which molecular traces of a key biomarker specific to Ph+ CML have been used as a primary endpoint for regulatory review. The comparison study also met its secondary endpoint, a difference in complete cytogenetic response (CCyR) in favor of Tasigna (5,6).

"We developed Tasigna to be a potent and selective inhibitor of Bcr-Abl, with the goal of eliminating the underlying cause of Ph+ CML. We now know that Tasigna reduces the level of Bcr-Abl faster and to a lower level than Gleevec, with profound implications for improving patients' outcomes," said David Epstein, President and CEO of Novartis Oncology and Novartis Molecular Diagnostics. "Molecular monitoring enables us to evaluate whether patients have achieved this deep level of CML residual disease, reducing the fundamental biomarker of leukemia to nearly undetectable levels."

The blood test used to determine molecular response can detect a single cell containing traces of Bcr-Abl in up to one mil
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
2. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
3. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
4. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
5. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
9. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Australia, March 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: ... liver cancer data has been accepted for late breaking ... the Liver,(EASL). Progen will also be presenting the results ... Cancer Research (AACR),Annual Meeting 2007. , ,In expectation ...
... - Tyrima Demonstrates Good Safety Profile and Excellent,Pharmacokinetic ... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a clinical stage ... the central,nervous system, today announced top-line results from ... candidate for the treatment,of depression and anxiety. In ...
Cached Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:7/25/2014)... (PRWEB) July 26, 2014 PersonalInjurySolicitorsIreland, ... legal help to people who have suffered from ... launch of both their new company, and a ... on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , ... The focus of the company is always on ...
(Date:7/25/2014)... Dallas, TX (PRWEB) July 26, 2014 ... China Laser Scanning Confocal Microscope Industry” is ... China Laser Scanning Confocal Microscope market. The ... information, including Laser Scanning Confocal Microscope definition, ... as industry overview. This research covers international market ...
(Date:7/25/2014)... According to a new market research report "Machine ... ultrasound emission, lubricating oil analysis, corrosion monitoring, motor ... Global Forecast to 2014 - 2020", published by ... to reach $2.50 at a CAGR of 7.16% ... data Tables and 57 Figures spread through 353 ...
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... and summary judgment in two DePuy Pinnacle hip lawsuits ... the way for the claims to go before a ... In an opinion rendered on July 18th, U.S. District ... ruled that the two Plaintiffs’ claims may proceed to ...
(Date:7/25/2014)... 2014 As reported by the New Orleans ... Increasing (7/3), the state of Louisiana has recently seen ... even than cocaine. Officials believe the increase is due to ... “form” of marijuana. However, both doctors and police confirm that ... as to call it “poison,” doctors have acknowledged that the ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2
... lowered chances of those under 5 getting the disease ... approval of a new, more broadly effective pneumococcal vaccine ... of pneumococcal disease in that age group, a new ... Food and Drug Administration approved PCV13 and the Advisory ...
... in rotator cuff a warning sign, but exercise regimens can ... As another baseball season nears, researchers report that preseason measurements ... pitchers at high risk of developing a shoulder injury during ... where, if they are weaker, players are more likely to ...
... reduces cholesterol without the troublesome side effects experienced by ... today in The New England Journal of Medicine ... Hopkins Medical Institutions, the Karolinska University Hospital and Institute, ... substance called Eprotirome in patients with high cholesterol. ...
... of losing weight, weight reduction also might negatively affect bones ... - breaking down old bone and forming new bone - ... reduced, causing increased fragility. In a new study, University of ... walking or jogging, did not prevent the increased bone turnover ...
... , ... seeks to market affordable and stylish prescription eyeglasses , ... New Jersey (PRWEB) March 11, 2010 -- GlassesUSA.com ... practical option in vision care. The partnership, in which Cardinal.com will promote GlassesUSA’s products ...
... VCAD invites ... ... the public to an evening presentation of fashion and costume history on Wednesday, March 17, ... the changing trends and styles of fashion from the 1890s through to the 1990s. , ...
Cached Medicine News:Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 3Health News:Thyroid hormone analogue for treating high cholesterol 2Health News:Weight-bearing exercise does not prevent increased bone turnover during weight loss 2Health News:GlassesUSA.com and Cardinal Health in Strategic Partnership 2Health News:Go Beyond Retro to Discover the World of 20th Century Fashion! 2
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Inquire...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
Medicine Products: